Plain-English translation of NCT06693908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called to see how well it works in reducing gut inflammation in people with moderate to severe ulcerative colitis. Researchers want to understand how the medication works in the intestines and whether it is safe and effective. The study will include 24 participants who will receive injections of the medication over a treatment period.
Many people with severe ulcerative colitis don't get better with current standard treatments, so doctors need to develop and test new options. This medication takes a different approach than older treatments, and this trial is designed to see if it can help patients whose disease hasn't responded to other therapies.
If you join this trial, you will receive subcutaneous injections (shots just under the skin) of the medication during the treatment period. The study will monitor how the treatment affects your gut inflammation, how your body processes the medication, and any side effects you experience. You'll likely have several clinic visits for blood tests, gut assessments, and check-ins with the research team to track your response to the treatment.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Germany
Phase
Safety & dosing / Early efficacy
Sponsor
Genentech, Inc.
Enrollment target
~24 participants
Started
March 2025
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.